ACCF/AHA 心力衰竭 C 期的管理。

Management of ACCF/AHA Stage C heart failure.

机构信息

Mechanical Circulatory Support & Heart Transplantation Program, Ahmanson-UCLA Cardiomyopathy Center, David Geffen School of Medicine, University of California, Los Angeles, 100 UCLA Medical Plaza, Suite 630 East, Los Angeles, CA 90095, USA.

出版信息

Cardiol Clin. 2014 Feb;32(1):73-93, viii. doi: 10.1016/j.ccl.2013.09.012.

DOI:10.1016/j.ccl.2013.09.012

PMID:24286580

Abstract

ACC Stage C heart failure includes those patients with prior or current symptoms of heart failure in the context of an underlying structural heart problem who are primarily managed with medical therapy. Although there is guideline-based medical therapy for those with heart failure with reduced ejection fraction (HFrEF), therapies in heart failure with preserved ejection fraction (HFpEF) have thus far proven elusive. Emerging therapies such as serelaxin are currently under investigation and may prove beneficial. The role of advanced surgical therapies, such as mechanical circulatory support, in this population is not well defined. Further investigation is warranted for these therapies in patients with Stage C heart failure.

摘要

ACC 阶段 C 心力衰竭包括那些在潜在结构性心脏问题背景下存在既往或当前心力衰竭症状且主要接受药物治疗的患者。尽管射血分数降低的心力衰竭（HFrEF）患者有基于指南的药物治疗，但射血分数保留的心力衰竭（HFpEF）患者的治疗方法迄今仍难以确定。新兴治疗方法，如 Serelaxin，目前正在研究中，可能有益。机械循环支持等先进的手术治疗方法在该人群中的作用尚未明确。这些治疗方法在 C 阶段心力衰竭患者中进一步研究是必要的。